DRI Healthcare Trust (TSE:DHT.UN) Given Average Rating of “Moderate Buy” by Analysts

Shares of DRI Healthcare Trust (TSE:DHT.UN) have been given a consensus rating of “Moderate Buy” by the six ratings firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is C$17.94.

Several equities analysts have recently issued reports on DHT.UN shares. Raymond James dropped their price target on shares of DRI Healthcare Trust from C$23.00 to C$22.00 in a research note on Wednesday, November 13th. CIBC cut their target price on DRI Healthcare Trust from C$19.50 to C$18.00 and set an “outperform” rating on the stock in a report on Thursday, December 12th. Finally, Scotiabank upped their price target on DRI Healthcare Trust from C$21.00 to C$22.00 and gave the company an “outperform” rating in a research report on Tuesday, October 8th.

DRI Healthcare Trust Trading Down 1.4 %

Shares of TSE DHT.UN opened at C$12.33 on Friday. The company has a 50 day simple moving average of C$12.23 and a 200 day simple moving average of C$12.57. DRI Healthcare Trust has a 1 year low of C$10.39 and a 1 year high of C$17.43.

DRI Healthcare Trust Company Profile

DRI Healthcare Trust is an open-ended trust that provides unitholders with differentiated exposure to the anticipated growth in the global pharmaceuticals and biotechnology markets. Its business model is focused on managing and growing a diversified portfolio of pharmaceutical royalties to deliver attractive growth in cash royalty receipts over the long term.